Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie L. Popplewell, Thomas Matthew Habermann, Joseph M. Herman, William H. Matsui, Richard J. Jones, Richard F. Ambinder

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% forAVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.

Original languageEnglish (US)
Pages (from-to)4129-4132
Number of pages4
JournalBlood
Volume119
Issue number18
DOIs
StatePublished - May 3 2012

Fingerprint

Hodgkin Disease
B-Lymphocytes
Bleomycin
Cells
Human Herpesvirus 4
Reed-Sternberg Cells
Dacarbazine
Vinblastine
Radiotherapy
Doxorubicin
Disease-Free Survival
Tumors
Survival Rate
Plasmas
Recurrence
Rituximab
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kasamon, Y. L., Jacene, H. A., Gocke, C. D., Swinnen, L. J., Gladstone, D. E., Perkins, B., ... Ambinder, R. F. (2012). Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood, 119(18), 4129-4132. https://doi.org/10.1182/blood-2012-01-402792

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. / Kasamon, Yvette L.; Jacene, Heather A.; Gocke, Christopher D.; Swinnen, Lode J.; Gladstone, Douglas E.; Perkins, Brandy; Link, Brian K.; Popplewell, Leslie L.; Habermann, Thomas Matthew; Herman, Joseph M.; Matsui, William H.; Jones, Richard J.; Ambinder, Richard F.

In: Blood, Vol. 119, No. 18, 03.05.2012, p. 4129-4132.

Research output: Contribution to journalArticle

Kasamon, YL, Jacene, HA, Gocke, CD, Swinnen, LJ, Gladstone, DE, Perkins, B, Link, BK, Popplewell, LL, Habermann, TM, Herman, JM, Matsui, WH, Jones, RJ & Ambinder, RF 2012, 'Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma', Blood, vol. 119, no. 18, pp. 4129-4132. https://doi.org/10.1182/blood-2012-01-402792
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-4132. https://doi.org/10.1182/blood-2012-01-402792
Kasamon, Yvette L. ; Jacene, Heather A. ; Gocke, Christopher D. ; Swinnen, Lode J. ; Gladstone, Douglas E. ; Perkins, Brandy ; Link, Brian K. ; Popplewell, Leslie L. ; Habermann, Thomas Matthew ; Herman, Joseph M. ; Matsui, William H. ; Jones, Richard J. ; Ambinder, Richard F. / Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. In: Blood. 2012 ; Vol. 119, No. 18. pp. 4129-4132.
@article{cff8f9e15ac1429cbb67d8e326426da6,
title = "Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma",
abstract = "In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69{\%} had stage IIB-IV disease; 8{\%} had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94{\%} forAVD and 79{\%} for bleomycin. After 6 cycles, 81{\%} of patients were in complete remission. Only 8{\%} received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83{\%} and 98{\%}, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.",
author = "Kasamon, {Yvette L.} and Jacene, {Heather A.} and Gocke, {Christopher D.} and Swinnen, {Lode J.} and Gladstone, {Douglas E.} and Brandy Perkins and Link, {Brian K.} and Popplewell, {Leslie L.} and Habermann, {Thomas Matthew} and Herman, {Joseph M.} and Matsui, {William H.} and Jones, {Richard J.} and Ambinder, {Richard F.}",
year = "2012",
month = "5",
day = "3",
doi = "10.1182/blood-2012-01-402792",
language = "English (US)",
volume = "119",
pages = "4129--4132",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

AU - Kasamon, Yvette L.

AU - Jacene, Heather A.

AU - Gocke, Christopher D.

AU - Swinnen, Lode J.

AU - Gladstone, Douglas E.

AU - Perkins, Brandy

AU - Link, Brian K.

AU - Popplewell, Leslie L.

AU - Habermann, Thomas Matthew

AU - Herman, Joseph M.

AU - Matsui, William H.

AU - Jones, Richard J.

AU - Ambinder, Richard F.

PY - 2012/5/3

Y1 - 2012/5/3

N2 - In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% forAVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.

AB - In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% forAVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.

UR - http://www.scopus.com/inward/record.url?scp=84860741107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860741107&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-402792

DO - 10.1182/blood-2012-01-402792

M3 - Article

VL - 119

SP - 4129

EP - 4132

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -